Bio-Path director resigns; board fails Nasdaq independence rules, cure period granted

BIO-PATH HOLDINGS, INC.

Martina Molsbergen resigned from board and all committees effective Feb 14, 2022, not due to disagreement.
Company no longer has majority independent directors or three independent audit committee members as required by Nasdaq.
Cure period expires at earlier of next annual meeting or Feb 14, 2023; board plans to appoint new independent director.
Non-compliance notified to Nasdaq on Feb 15, 2022.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Martina Molsbergen

member of the Board and all committees of the Board

BPTH · BIO-PATH HOLDINGS, INC.

Effective: 2022-02-14
Filed: February 18, 2022, 6:59 PM ET

On February 14, 2022, Martina Molsbergen resigned from her position as a member of the Board and all committees of the Board on which she served

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martina Molsbergen resigned as member of the Board and all committees of the Board at BIO-PATH HOLDINGS, INC..

Action: resigned
Role: member of the Board and all committees of the Board

Exact text from the filing

On February 14, 2022, Martina Molsbergen resigned from her position as a member of the Board and all committees of the Board on which she served

View on SEC.gov

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-22-001442

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.